Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. If you're looking to invest in the small-cap biotech sector, patience is essential. Most of these companies are still clinical-stage and do not yet have commercially available drugs or therapeutics. That also means negative earnings and little to no revenue. Success often hinges on the outcome of a single clinical-stage program. Elon Musk's Starlink project is generating major speculation ahead of a potential IPO that some analysts believe could reach a historic $100 billion valuation. According to James Altucher, there may be a smart "backdoor" way for everyday investors to position ahead of that event without needing traditional IPO access — and he says it can be done for under $100. He's also sharing a free ticker tied to this trend for anyone who wants to take a closer look. Click here to learn more Even when a product advances through trials, profitability can still be years away. Analyst coverage—and the institutional investment that often follows—typically arrives only after clear commercial progress. Still, getting in on a medical stock that succeeds can feel like winning the lottery: a single breakthrough can produce 3x, 5x, or even 10x returns, while many other names never pan out. That's why many investors who follow penny stocks spread a lump sum across multiple biotech companies. If this is a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry substantial risk but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in the space, Mainz Biomed already has a commercial product: ColoAlert, the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a German digital-health pioneer. With more than 60,000 new colorectal cancer cases annually in Germany, the opportunity is meaningful. The company is also developing a non-invasive blood-based screening test for early pancreatic cancer and reported positive topline results in October. That program, however, remains years away from potential commercial approval. Risks are significant. ColoAlert is not yet available in the United States, and despite early European sales and plans for South America, overall revenue remains limited. The company acknowledged this in its Sept. 26 SEC filing by including “going concern” language, and it has filed a $150 million mixed shelf offering. For now, that financing is helping keep the MYNZ share price above $1 to avoid a delisting notice. Mainz Biomed must generate meaningful revenue to materially change the company's outlook. If it succeeds, even a relatively small investment could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech that proposes a potentially disruptive antiviral approach—but also presents the financial risks typical of speculative biotechs. The company is developing a novel class of antiviral therapies built on its proprietary "nanoviricide" platform. These drug candidates are designed to mimic human cell surfaces, luring viruses to bind with them and neutralizing the pathogens before they infect real cells. If validated in human trials, this approach could represent a fundamentally new method for treating infectious disease. NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data. Like many micro-cap biotechs, NanoViricides is pre-revenue and dependent on fresh capital to advance its programs. Recent filings show limited cash on hand, and investors should expect the possibility of future dilution. Still, if one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a true moonshot in the antiviral space.
| 
